• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在资源有限的情况下提供 COVID-19 恢复期血浆。

Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.

机构信息

Department of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Oklahoma/Texas/and Arkansas Blood Institute, Oklahoma City, Oklahoma, USA.

出版信息

Transfusion. 2020 Dec;60(12):2828-2833. doi: 10.1111/trf.16118. Epub 2020 Oct 8.

DOI:10.1111/trf.16118
PMID:32989778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7536906/
Abstract

BACKGROUND

Arkansas is a rural state of 3 million people. It is ranked fifth for poverty nationally. The first case of coronavirus disease 2019 (COVID-19) in Arkansas occurred on 11 March 2020. Since then, approximately 8% of all Arkansans have tested positive. Given the resource limitations of Arkansas, COVID-19 convalescent plasma (CCP) was explored as a potentially lifesaving, therapeutic option. Therefore, the Arkansas Initiative for Convalescent Plasma was developed to ensure that every Arkansan has access to this therapy.

STUDY DESIGN AND METHOD

This brief report describes the statewide collaborative response from hospitals, blood collectors, and the Arkansas Department of Health (ADH) to ensure that CCP was available in a resource-limited state.

RESULTS

Early contact tracing by ADH identified individuals who had come into contact with "patient zero" in early March. Within the first week, 32 patients tested positive for COVID-19. The first set of CCP collections occurred on 9 April 2020. Donors had to be triaged carefully in the initial period, as many had recently resolved their symptoms. From our first collections, with appropriate resource and inventory management, we collected sufficient CCP to provide the requested number of units for every patient treated with CCP in Arkansas.

CONCLUSIONS

The Arkansas Initiative, a statewide effort to ensure CCP for every patient in a resource-limited state, required careful coordination among key players. Collaboration and resource management was crucial to meet the demand of CCP products and potentially save lives.

摘要

背景

阿肯色州是一个拥有 300 万人口的农村州,其贫困率在全美排名第五。阿肯色州首例 2019 年冠状病毒病(COVID-19)病例于 2020 年 3 月 11 日出现。此后,大约 8%的阿肯色人检测呈阳性。鉴于阿肯色州资源有限,COVID-19 恢复期血浆(CCP)被探索为一种潜在的救生治疗选择。因此,阿肯色州恢复期血浆倡议得以开发,以确保每个阿肯色人都能获得这种治疗。

研究设计和方法

本简要报告描述了全州范围内医院、血液采集者和阿肯色州卫生部(ADH)之间的协作反应,以确保在资源有限的州中提供 CCP。

结果

ADH 的早期接触者追踪确定了 3 月早些时候与“零号病人”接触过的人。在第一周内,有 32 名患者 COVID-19 检测呈阳性。第一批 CCP 采集于 2020 年 4 月 9 日进行。在最初阶段,必须仔细对捐赠者进行分类,因为许多人最近已缓解了症状。通过我们的首次采集,通过适当的资源和库存管理,我们收集了足够的 CCP,为阿肯色州接受 CCP 治疗的每位患者提供了所需数量的单位。

结论

阿肯色州倡议是一项全州范围内的努力,旨在确保资源有限的州中每个患者都能获得 CCP,这需要关键参与者之间的精心协调。协作和资源管理对于满足 CCP 产品的需求并可能挽救生命至关重要。

相似文献

1
Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.在资源有限的情况下提供 COVID-19 恢复期血浆。
Transfusion. 2020 Dec;60(12):2828-2833. doi: 10.1111/trf.16118. Epub 2020 Oct 8.
2
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.COVID-19 患者在出现血清转换之前使用门诊获得的 COVID-19 恢复期血浆。
Front Immunol. 2021 Sep 14;12:739037. doi: 10.3389/fimmu.2021.739037. eCollection 2021.
3
Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.抗击 SARS-CoV-2 恢复期血浆库的准备和活动:未来紧急情况的组织模型。
Transfus Apher Sci. 2021 Aug;60(4):103154. doi: 10.1016/j.transci.2021.103154. Epub 2021 May 7.
4
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.中国武汉 COVID-19 恢复期血浆采集试点项目的可行性。
Transfusion. 2020 Aug;60(8):1773-1777. doi: 10.1111/trf.15921. Epub 2020 Jul 31.
5
Screening donors for COVID-19 convalescent plasma.对 COVID-19 恢复期血浆供者进行筛查。
Transfusion. 2021 Apr;61(4):1047-1052. doi: 10.1111/trf.16253. Epub 2021 Feb 1.
6
Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.推动 COVID-19 恢复期血浆供应的因素:基于需求、生产和供应模型的分析。
Transfusion. 2021 May;61(5):1370-1376. doi: 10.1111/trf.16317. Epub 2021 Feb 16.
7
Challenges in Establishing a Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Donation Program in a Multicultural Environment.在多元文化环境中建立 2019 冠状病毒病(COVID-19)恢复期血浆捐献计划面临的挑战。
Arch Pathol Lab Med. 2021 Dec 1;145(12):1479-1484. doi: 10.5858/arpa.2021-0198-SA.
8
Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.快速成功实施 COVID-19 恢复期血浆计划——南非经验。
Viruses. 2021 Oct 12;13(10):2050. doi: 10.3390/v13102050.
9
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.在资源有限的情况下,使用两单位恢复期血浆治疗 COVID-19 患者。
Lab Med. 2022 Nov 3;53(6):623-628. doi: 10.1093/labmed/lmac055.
10
Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.8000 例美国首次恢复期血浆捐献者中 SARS-CoV-2 抗体的纵向分析。
Transfusion. 2021 Apr;61(4):1141-1147. doi: 10.1111/trf.16291. Epub 2021 Feb 22.

引用本文的文献

1
The CTSA University of Texas Health Science Center (UTHSC) Northeast-Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical Research.CTSA 德克萨斯大学健康科学中心(UTHSC)东北-泰勒和里奥格兰德河谷成功案例:农村、服务不足的学术社区如何快速构建强大的 COVID-19 临床研究协作引擎。
J Health Care Poor Underserved. 2022;33(1):517-527. doi: 10.1353/hpu.2022.0040.
2
Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.系统评价和随机对照试验的荟萃分析,测试恢复期血浆治疗 2019 年冠状病毒病(COVID-19)的安全性和有效性:实践证据和对研究的影响。
Transfus Med. 2021 Dec;31(6):409-420. doi: 10.1111/tme.12803. Epub 2021 Jun 29.
3
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.恢复期血浆用于 COVID-19 的预防和治疗:系统评价和定量分析。
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.

本文引用的文献

1
Convalescent plasma: new evidence for an old therapeutic tool?康复血浆:一种古老治疗手段的新证据?
Blood Transfus. 2016 Mar;14(2):152-7. doi: 10.2450/2015.0131-15. Epub 2015 Nov 6.
2
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.恢复期血浆治疗可降低严重大流行流感 A(H1N1)2009 病毒感染患者的死亡率。
Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.
3
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?荟萃分析:用于西班牙流感肺炎的恢复期血液制品:未来治疗H5N1的方法?
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.